| Name | Title | Contact Details |
|---|---|---|
Keleigh Pearson |
Assistant General Counsel - NABU | Profile |
Jeff Gold |
Chief IP Counsel | Profile |
Rachel Lei |
General Counsel and Corporate Secretary | Profile |
Kenneth Bonnell |
Vice President of Quality and Regulatory Affairs | Profile |
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Metabolix, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Woodside Senior Communities is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…
BioXcel is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.